- Johnson, Douglas B;
- Atkins, Michael B;
- Hennessy, Cassandra;
- Wise-Draper, Trisha;
- Heilman, Hannah;
- Awosika, Joy;
- Bakouny, Ziad;
- Labaki, Chris;
- Saliby, Renee Maria;
- Hwang, Clara;
- Singh, Sunny RK;
- Balanchivadze, Nino;
- Friese, Christopher R;
- Fecher, Leslie A;
- Yoon, James J;
- Hayes-Lattin, Brandon;
- Bilen, Mehmet A;
- Castellano, Cecilia A;
- Lyman, Gary H;
- Tachiki, Lisa;
- Shah, Sumit A;
- Glover, Michael J;
- Flora, Daniel B;
- Wulff-Burchfield, Elizabeth;
- Kasi, Anup;
- Abbasi, Saqib H;
- Farmakiotis, Dimitrios;
- Viera, Kendra;
- Klein, Elizabeth J;
- Weissman, Lisa B;
- Jani, Chinmay;
- Puc, Matthew;
- Fahey, Catherine C;
- Reuben, Daniel Y;
- Mishra, Sanjay;
- Beeghly-Fadiel, Alicia;
- French, Benjamin;
- Warner, Jeremy L;
- COVID-19 and Cancer Consortium
Introduction
COVID-19 particularly impacted patients with co-morbid conditions, including cancer. Patients with melanoma have not been specifically studied in large numbers. Here, we sought to identify factors that associated with COVID-19 severity among patients with melanoma, particularly assessing outcomes of patients on active targeted or immune therapy.Methods
Using the COVID-19 and Cancer Consortium (CCC19) registry, we identified 307 patients with melanoma diagnosed with COVID-19. We used multivariable models to assess demographic, cancer-related, and treatment-related factors associated with COVID-19 severity on a 6-level ordinal severity scale. We assessed whether treatment was associated with increased cardiac or pulmonary dysfunction among hospitalized patients and assessed mortality among patients with a history of melanoma compared with other cancer survivors.Results
Of 307 patients, 52 received immunotherapy (17%), and 32 targeted therapy (10%) in the previous 3 months. Using multivariable analyses, these treatments were not associated with COVID-19 severity (immunotherapy OR 0.51, 95% CI 0.19 - 1.39; targeted therapy OR 1.89, 95% CI 0.64 - 5.55). Among hospitalized patients, no signals of increased cardiac or pulmonary organ dysfunction, as measured by troponin, brain natriuretic peptide, and oxygenation were noted. Patients with a history of melanoma had similar 90-day mortality compared with other cancer survivors (OR 1.21, 95% CI 0.62 - 2.35).Conclusions
Melanoma therapies did not appear to be associated with increased severity of COVID-19 or worsening organ dysfunction. Patients with history of melanoma had similar 90-day survival following COVID-19 compared with other cancer survivors.